CAR-T CELL THERAPY HUB · RESOURCE LIBRARY

Guiding Every Step of the CAR-T Cell Therapy Journey

Curated, practice-ready resources supporting the safe, effective implementation of CAR-T cell therapy — organized into Clinical Education, Agent-Specific Resources, and Example SOPs & Documents.

3

Core Sections

7

Agent Profiles

2

Example SOPs

4

Toolkits

CAR-T Patient Journey

Referral

Apheresis

Manufacturing

Bridging Therapy

Lymphodepletion

Infusion & Monitoring

01 · FOUNDATIONS

Clinical Education

Foundational knowledge to help your team understand and operationalize CAR-T cell therapy.

Comparison of CAR-T Cell Therapies

Compare approved CAR-T therapies by disease state, including dosing, safety, and manufacturing considerations.

View Resource →

Managing CAR-T Immune-Related Adverse Events

Review recognition, grading, and management of CAR-T toxicities, including CRS and ICANS.

View Resource →

Outpatient CAR-T: Same Powerful Therapy, Different Care Model

Explore outpatient CAR-T models, including patient selection, monitoring, escalation, and program readiness.

View Resource →

02 · UP CLOSE SERIES

Agent-Specific Resources

A comparison guide plus a closer look at every FDA-approved CAR-T therapy — target antigen, brand name, and where to go deeper.

Obecatagene Autoleucel

AUCATZYL®

View →

Tisagenlecleucel

KYMRIAH®

View →

Axicabtagene Ciloleucel

YESCARTA®

View →

Brexucabtagene Autoleucel

TECARTUS®

View →

Lisocabtagene Maraleucel

BREYANZI®

View →

Idecabtagene Vicleucel

ABECMA®

View →

Ciltacabtagene Autoleucel

CARVYKTI®

View →

Target: CD19

Target: CD19

Target: CD19

Target: CD19

Target: CD19

Target: BCMA

03 · REAL-WORLD PRACTICE

Example SOPs & Documents

Two standard operating procedures and three clinic implementation toolkits, shared by NCODA member practices.

SOP Document

CAR-T Center Coordination With a Community Cancer Center

This example standard operating procedure (SOP) provides a framework for CAR-T centers to coordinate care with community cancer centers throughout referral, patient evaluation, bridging therapy, lymphodepletion, infusion, acute toxicity management, transition of care, and long-term follow-up.

View Resource →

SOP Document

Community Practice Coordination With a CART-T Treatment Center

This example standard operating procedure provides a framework for community oncology practices coordinating care with a CAR-T treatment center from early referral through long-term follow-up.

View Resource →

TOOLKIT

Apheresis & Bridging Therapy Coordination

Scheduling and coordinating cell collection and any bridging therapy before manufacturing.

View Resource →

TOOLKIT

Infusion & Care Coordination

Inpatient/outpatient coordination for the infusion day and immediate monitoring window.

In Development →

TOOLKIT

Long-Term Follow-Up & REMS Compliance

Ongoing monitoring requirements and REMS documentation for CAR-T recipients.

In Development →

TOOLKIT

Long-Term Follow-Up & REMS Compliance

Ongoing monitoring requirements and REMS documentation for CAR-T recipients.

In Development →

RECOMMENDED READING

1

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.

2

Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.

3

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.

4

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716.

Help Build the CAR-T Cell Therapy Hub

NCODA members can share protocols, request specific SOPs, or connect with our team.